Contact us

Advancing immunotherapies
with avidity intelligence

Most immunotherapies fail because the best candidate was never found.
We help you uncover it faster, with greater biological confidence.

Advancing immunotherapies
with avidity intelligence

Most immunotherapies fail because the best candidate was never found.
We help you uncover it faster, with greater biological confidence.

Advancing immunotherapies
with avidity intelligence

Most immunotherapies fail because the best candidate was never found.
We help you uncover it faster, with greater biological confidence.

Advancing immunotherapies
with avidity intelligence

Most immunotherapies fail because the best candidate was never found. We help you uncover it faster, with greater biological confidence.

our proprietary technologyA new dimension in immunotherapy R&D

Our platform redefines how potent immune cells are identified—measuring cellular avidity to uncover what truly drives therapeutic success.

Physiological Relevance

Captures the full complexity of live immune–target cell interactions, delivering insights that better reflect in-vivo therapeutic behaviour.

High Throughput

Analyses tens of thousands of single-cell interactions per run—and scales to millions, enabling comprehensive profiling of diverse immune cell populations.

Gentle

Maintains cell viability and functionality for immediate downstream testing, seamlessly integrating into your existing R&D pipeline.

Fully Adaptable

Compatible with a wide range of adherent target cells and immune cell types, including TCR-T, CAR-T, NK, and beyond—across various solid tumour indications.

servicesPreclinical avidity services for every stage of your programme

From initial lead identification through to pre-IND candidate confirmation, our platform adds a layer of translational insight that standard assays cannot provide — helping you advance the right candidates with confidence.
financial-information

Immunotherapy validation

Completing the immune cell data set and ranking candidates for confident translation.

Cell

Immunotherapy discovery

Identifying target-specific leads amongst millions of potential candidates.

Speak to one of our scientists to explore how we can support your projects

our proprietary technologyA new dimension in immunotherapy R&D

Our platform redefines how potent immune cells are identified—measuring cellular avidity to uncover what truly drives therapeutic success.

Physiological Relevance

Captures the full complexity of live immune–target cell interactions, delivering insights that better reflect in-vivo therapeutic behaviour.

High Throughput

Analyses tens of thousands of single-cell interactions per run—and scales to millions, enabling comprehensive profiling of diverse immune cell populations.

Gentle

Maintains cell viability and functionality for immediate downstream testing, seamlessly integrating into your existing R&D pipeline.

Fully Adaptable

Compatible with a wide range of adherent target cells and immune cell types, including TCR-T, CAR-T, NK, and beyond—across various solid tumour indications.

servicesPreclinical avidity services for every stage of your programme

From initial lead identification through to pre-IND candidate confirmation, our platform adds a layer of translational insight that standard assays cannot provide — helping you advance the right candidates with confidence.
financial-information

Immunotherapy validation

Completing the immune cell data set and ranking candidates for confident translation.

Cell

Immunotherapy discovery

Identifying target-specific leads amongst millions of potential candidates.

Speak to one of our scientists to explore how we can support your projects

testimonialsTrusted by scientists developing
the next generation of therapies

partnersOur partners

testimonialsTrusted by scientists developing
the next generation of therapies

testimonialsTrusted by scientists developing
the next generation of therapies

Contact us today to explore how
we can support your R&D projects